Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 1 de 1
Filtrer
Plus de filtres











Base de données
Gamme d'année
1.
J Immunol ; 154(1): 281-9, 1995 Jan 01.
Article de Anglais | MEDLINE | ID: mdl-7995947

RÉSUMÉ

Human NK cells can be separated into two functionally distinct subpopulations based on the ability to rapidly respond to IL-2 by adherence to solid surfaces. To determine functions of the NK cell subsets in solid tumor tissues, adherent (A) and nonadherent (NA) NK cells were evaluated for their ability to infiltrate multicellular tumor spheroids in vitro, to kill carcinoma (CA) cell targets in these spheroids, and to mediate antitumor activity in vivo. A-NK cells were less cytolytic than NA-NK cells against CA targets in single cell suspensions or in monolayers. However, A-NK cells showed a significantly better ability than NA-NK cells to infiltrate tumor tissues and kill tumor cells in spheroids of human squamous cell CA of the head and neck or breast CA. Perilesional delivery of human A-NK cells and IL-2 resulted in regression of established human squamous cell carcinoma of the head and neck tumors growing subcutaneously in immunosuppressed nude mice. Similarly, in a xenograft model of human gastric CA metastatic to liver of nude mice, a single intrasplenic injection of A-NK cells in combination with i.p. infusions of IL-2 significantly reduced the number of established hepatic metastases (p < 0.007) and prolonged survival of the mice (p < 0.003). In contrast, NA-NK cells were ineffective in either of the in vivo xenograft tumor models. These findings demonstrate that A-NK cells represent a biologically unique and important subset of NK cells that, in contrast to the rest of NK cells, function as effector cells in solid tumor tissues and, consequently, have a great antitumor therapeutic potential.


Sujet(s)
Adénocarcinome/thérapie , Tumeurs du sein/thérapie , Carcinome épidermoïde/thérapie , Tumeurs de la tête et du cou/thérapie , Immunothérapie adoptive , Interleukine-2/pharmacologie , Cellules LAK/immunologie , Tumeurs du foie/secondaire , Sous-populations de lymphocytes/immunologie , Adénocarcinome/immunologie , Animaux , Tumeurs du sein/immunologie , Carcinome épidermoïde/immunologie , Adhérence cellulaire , Mouvement cellulaire , Tests de cytotoxicité immunologique , Femelle , Tumeurs de la tête et du cou/immunologie , Humains , Interleukine-2/usage thérapeutique , Cellules LAK/effets des médicaments et des substances chimiques , Cellules LAK/transplantation , Tumeurs du foie/thérapie , Sous-populations de lymphocytes/effets des médicaments et des substances chimiques , Sous-populations de lymphocytes/transplantation , Souris , Souris de lignée BALB C , Souris nude , Transplantation tumorale , Organoïdes , Tumeurs de l'estomac/anatomopathologie , Transplantation hétérologue , Cellules cancéreuses en culture
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE